Loading...
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramu...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4610887/ https://ncbi.nlm.nih.gov/pubmed/26508880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S79145 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|